VivoSeq
Oncology

Kaposi Sarcoma

0

Pipeline Programs↗

10

Active Trials↗

2

Companies Involved↗

Kaposi Sarcoma is an early-stage landscape with 0 programs across 2 companies. The most active players are Vasgene Therapeutics, Inc, Navidea Biopharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

19/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

23/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

V

Vasgene Therapeutics, Inc

0 programs

PreclinicalN

Navidea Biopharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

22

clinical trials

Recruiting7 · 32%
Completed5 · 23%
Withdrawn3 · 14%
Unknown status2 · 9%
Active, not recruiting2 · 9%
Terminated2 · 9%
Other1 · 5%

Clinical Trials

Trial Activity

22 trials

Trial of Ixazomib for Kaposi Sarcoma
Recruiting·AAIDS Malignancy Consortium·Phase 2·NCT04305691·41 enrolled
A Study of sEphB4-HSA in Kaposi Sarcoma
Recruiting·VVasgene Therapeutics, Inc·Phase 2·NCT03993106·65 enrolled
Propranolol for the Treatment of Kaposi Sarcoma in Adults
Recruiting·WWashington University School of Medicine·Phase 2·NCT06445166·25 enrolled
Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT07308886·55 enrolled
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma
Recruiting·National Cancer Institute (NCI)·Phase 1/2·NCT04941274·86 enrolled
PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma
Recruiting·National Cancer Institute (NCI)·Phase 1/2·NCT04303117·80 enrolled
Precision Imaging to Evaluation Kaposi Sarcoma (PRIME-KS)
Recruiting·WWashington University School of Medicine·Preclinical·NCT06898203·300 enrolled
Pomalidomide Treatment in Patients With Kaposi Sarcoma
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT04577755·45 enrolled
Kaposi Sarcoma Chemotherapy and Research (KS-CARE)
Active, not recruiting·UUNC Lineberger Comprehensive Cancer Center·N/A·NCT06480773·127 enrolled
A Study of Propranolol to Treat Kaposi Sarcoma
Not yet recruiting·AAIDS Malignancy Consortium·Phase 2·NCT05797662·25 enrolled
An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)
Completed·NNavidea Biopharmaceuticals·Phase 1·NCT03157167·15 enrolled
sEphB4-HSA in Treating Patients With Kaposi Sarcoma
Completed·AAIDS Malignancy Consortium·Phase 2·NCT02799485·23 enrolled
Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma
Completed·UUniversity of California, San Francisco·Phase 1·NCT03316274·12 enrolled
Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma
Completed·AAIDS Malignancy Consortium·Phase 2·NCT03077451·36 enrolled
Pomalidomide for Kaposi Sarcoma in People With or Without HIV
Completed·National Cancer Institute (NCI)·Phase 1/2·NCT01495598·28 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)